Twist Bioscience (TWST)


Market Price (11/19/2026): $118.18 | Market Cap: $8.1 BilSector: Health Care | Industry: Biotechnology

Twist Bioscience (TWST)


Market Price (11/19/2026): $118.18
Market Cap: $8.1 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more.

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -132 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -29%

Stock price has recently run up significantly
6M Rtn6 month market price return is 117%, 12M Rtn12 month market price return is 347%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9.0%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.0%

Key risks
TWST key risks include [1] its consistent inability to achieve profitability amid significant cash burn, Show more.

0 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more.
1 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -132 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -29%
3 Stock price has recently run up significantly
6M Rtn6 month market price return is 117%, 12M Rtn12 month market price return is 347%
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -9.0%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.0%
7 Key risks
TWST key risks include [1] its consistent inability to achieve profitability amid significant cash burn, Show more.

TWST in ETFs

Weight = TWST's share of each fund

VTI0.01%
ITOT0.01%
IWM0.27%
VB0.13%
ARKK2.9%
XBI1.3%
IWO0.48%
IBB0.47%
+11 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 17: up 6.6% in one day (S&P 500 down 1.0%)
The stock gained today without specific company news in our feed. This occurred while the S&P 500 declined.

Down 39.4% from its Oct 28 high to Nov 16, up 10.8% since (S&P 500 down 4.2%)
The stock saw a significant decline as the broader market reacted to growing concerns about tech and AI stocks, with headlines questioning a potential bubble and punishing the sector. Market unease about tech and AI was highlighted on October 30 and November 5, correlating with the steepest drops.

Nov 12: down 6.8% on its earnings report (S&P 500 down 0.4%)
The stock declined after Twist Bioscience reported a fiscal 2026 Q4 loss of $0.32 per share, despite beating revenue and loss per share estimates. This occurred while the S&P 500 also fell.

Show more
Prices as of 11/18/2026

Nov 17: up 6.6% in one day (S&P 500 down 1.0%)
The stock gained today without specific company news in our feed. This occurred while the S&P 500 declined.

Down 39.4% from its Oct 28 high to Nov 16, up 10.8% since (S&P 500 down 4.2%)
The stock saw a significant decline as the broader market reacted to growing concerns about tech and AI stocks, with headlines questioning a potential bubble and punishing the sector. Market unease about tech and AI was highlighted on October 30 and November 5, correlating with the steepest drops.

Nov 12: down 6.8% on its earnings report (S&P 500 down 0.4%)
The stock declined after Twist Bioscience reported a fiscal 2026 Q4 loss of $0.32 per share, despite beating revenue and loss per share estimates. This occurred while the S&P 500 also fell.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 27.1% change in TWST stock from 7/31/2026 to 11/18/2026 was primarily driven by a 22.3% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)91.55116.3527.1%
Change Contribution By: 
Total Revenues ($ Mil)40945912.2%
P/S Multiple13.816.922.3%
Shares Outstanding (Mil)6267-7.4%
Cumulative Contribution27.1%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
TWST27.1% 
Market (SPY)-2.0%42.4%
Sector (XLV)11.9%26.8%

Fundamental Drivers

The 99.1% change in TWST stock from 4/30/2026 to 11/18/2026 was primarily driven by a 85.1% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)58.45116.3599.1%
Change Contribution By: 
Total Revenues ($ Mil)39245917.3%
P/S Multiple9.116.985.1%
Shares Outstanding (Mil)6167-8.3%
Cumulative Contribution99.1%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
TWST99.1% 
Market (SPY)2.1%44.8%
Sector (XLV)25.1%18.9%

Fundamental Drivers

The 253.8% change in TWST stock from 10/31/2025 to 11/18/2026 was primarily driven by a 209.8% change in the company's P/S Multiple.
(LTM values as of)1031202511182026Change
Stock Price ($)32.89116.35253.8%
Change Contribution By: 
Total Revenues ($ Mil)36245926.8%
P/S Multiple5.416.9209.8%
Shares Outstanding (Mil)6067-10.0%
Cumulative Contribution253.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
TWST253.8% 
Market (SPY)8.2%47.3%
Sector (XLV)27.7%26.8%

Fundamental Drivers

The 638.3% change in TWST stock from 10/31/2023 to 11/18/2026 was primarily driven by a 342.0% change in the company's P/S Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)15.76116.35638.3%
Change Contribution By: 
Total Revenues ($ Mil)23545995.1%
P/S Multiple3.816.9342.0%
Shares Outstanding (Mil)5767-14.4%
Cumulative Contribution638.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
TWST638.3% 
Market (SPY)81.1%47.5%
Sector (XLV)52.9%33.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
TWST Return-45%-69%55%26%-32%267%-18%
Peers Return15%-61%-3%-21%-12%60%-51%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
TWST Win Rate33%25%50%50%42%73% 
Peers Win Rate59%25%50%45%43%53% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
TWST Max Drawdown-64%-74%-63%-38%-55%-49% 
Peers Max Drawdown-31%-67%-52%-53%-56%-45% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: DNA, ILMN, TMO, CDXS, TXG. See TWST Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventTWSTS&P 500
2025 US Tariff Shock
  % Loss-41.3%-18.8%
  % Gain to Breakeven70.4%23.1%
  Time to Breakeven258 days79 days
2024 Yen Carry Trade Unwind
  % Loss-16.5%-7.8%
  % Gain to Breakeven19.8%8.5%
  Time to Breakeven112 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-40.6%-9.5%
  % Gain to Breakeven68.4%10.5%
  Time to Breakeven35 days24 days
2023 SVB Regional Banking Crisis
  % Loss-52.0%-6.7%
  % Gain to Breakeven108.4%7.1%
  Time to Breakeven76 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-68.5%-24.5%
  % Gain to Breakeven217.8%32.4%
  Time to Breakeven1464 days427 days
2020 COVID-19 Crash
  % Loss-30.7%-33.7%
  % Gain to Breakeven44.3%50.9%
  Time to Breakeven8 days140 days

Compare to DNA, ILMN, TMO, CDXS, TXG

In The Past

Twist Bioscience's stock fell -41.3% during the 2025 US Tariff Shock. Such a loss loss requires a 70.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventTWSTS&P 500
2025 US Tariff Shock
  % Loss-41.3%-18.8%
  % Gain to Breakeven70.4%23.1%
  Time to Breakeven258 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-40.6%-9.5%
  % Gain to Breakeven68.4%10.5%
  Time to Breakeven35 days24 days
2023 SVB Regional Banking Crisis
  % Loss-52.0%-6.7%
  % Gain to Breakeven108.4%7.1%
  Time to Breakeven76 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-68.5%-24.5%
  % Gain to Breakeven217.8%32.4%
  Time to Breakeven1464 days427 days
2020 COVID-19 Crash
  % Loss-30.7%-33.7%
  % Gain to Breakeven44.3%50.9%
  Time to Breakeven8 days140 days

Compare to DNA, ILMN, TMO, CDXS, TXG

In The Past

Twist Bioscience's stock fell -41.3% during the 2025 US Tariff Shock. Such a loss loss requires a 70.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Twist Bioscience (TWST)

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacturing and sale of synthetic DNA-based products. The company's core innovation lies in its proprietary DNA synthesis platform, which enables the precise and high-throughput "writing" of DNA onto silicon chips. This unique technological capability allows Twist Bioscience to produce custom DNA sequences with accuracy and at scale.

Leveraging this advanced platform, Twist Bioscience offers a diverse portfolio of products and services. Its main offerings include synthetic genes, which are foundational components for various biotechnological applications, and tools designed for sample preparation, critical for modern genetic sequencing and analysis. Additionally, the company develops comprehensive antibody libraries, which are valuable resources for pharmaceutical companies engaged in drug discovery and development initiatives.

Twist Bioscience primarily serves customers within the biotechnology, pharmaceutical, and academic research sectors. Through strategic collaborations, it supports areas such as clinical genetic services, the development of advanced sequencing tools, and therapeutic antibody discovery. The company is also exploring cutting-edge applications, including the use of DNA as a novel medium for digital data storage, highlighting its forward-looking approach to expanding its market reach.

AI Analysis | Feedback

Here are 1-3 brief analogies for Twist Bioscience:

  • Like a specialized manufacturer such as **Intel** or **TSMC**, but they "print" synthetic DNA on silicon chips for biological applications instead of computer chips.
  • **Seagate** or **Western Digital**, but for storing digital information within DNA.
  • The "Intel Inside" of synthetic biology, providing the core DNA building blocks for drug discovery and other research applications.

AI Analysis | Feedback

  • Synthetic genes: Custom-made DNA sequences for research and development.
  • Tools for sample preparation: Products designed to prepare biological samples for advanced analysis.
  • Antibody libraries: Collections of diverse antibodies used in the discovery and development of new therapeutic drugs.
  • DNA as a digital data storage medium: Utilizing synthetic DNA to store digital information.

AI Analysis | Feedback

Twist Bioscience (TWST) primarily sells its synthetic DNA-based products and services to other companies and research institutions.

Based on the provided information, its major customers and collaboration partners include:

  • Victorian Clinical Genetic Services
  • Vivlion GmbH
  • Kyowa Kirin Co., Ltd. (TYO: 4151)
  • deepCDR Biologics AG
  • Centogene N.V (NASDAQ: CNTG)
  • Boehringer Ingelheim International GmbH

AI Analysis | Feedback

null

AI Analysis | Feedback

Emily Leproust, CEO, Co-Founder & Board Member

Emily Leproust is the CEO and a co-founder of Twist Bioscience, which she established in 2013. She is recognized as a pioneer in high-throughput DNA synthesis. Before co-founding Twist Bioscience, Dr. Leproust held various escalating positions at Agilent Technologies, including Director of Applications and Chemistry R&D for Genomics, where she was instrumental in architecting the successful SureSelect product line and developing the Oligo Library Synthesis technology. She is also a co-founder of Petri, an accelerator dedicated to startups in engineering and biology.

Adam Laponis, Chief Financial Officer

Adam Laponis serves as the Chief Financial Officer for Twist Bioscience.

Patrick Finn, President and Chief Operating Officer

Patrick Finn was promoted to President and Chief Operating Officer of Twist Bioscience in October 2022, having joined the company in 2015. Prior to this role, he served as Chief Commercial Officer starting in 2019 and as Vice President of Sales and Marketing upon joining in 2015. Dr. Finn previously held the position of Vice President of Sales at Enzymatics (which was later acquired by QIAGEN), where he oversaw commercial activities for North America and Europe. His extensive career also includes leadership roles at Agilent Technologies as Director of Business Development, Director of Product Development for Beckman Coulter, and various technical positions at Invitrogen and GE Healthcare/Amersham International.

Siyuan Chen, Chief Technology Officer

Siyuan Chen holds the position of Chief Technology Officer at Twist Bioscience.

Angela Bitting, Chief ESG Officer, Senior Vice President of Corporate Affairs

Angela Bitting is the Chief ESG Officer and Senior Vice President of Corporate Affairs at Twist Bioscience.

AI Analysis | Feedback

Here are the key risks to the business of Twist Bioscience (TWST):
  1. Persistent Unprofitability and High Cash Burn: Twist Bioscience has not yet achieved profitability, consistently reporting net operating losses and requiring significant capital to fund its operations and scale its proprietary platform. Despite strong revenue growth, the company faces substantial cash burn, which is a key financial concern for investors.
  2. Technological and Competitive Risk: The synthetic biology and DNA synthesis markets are characterized by rapid technological advancements. Twist Bioscience's proprietary silicon-based DNA synthesis platform, while a significant competitive advantage, faces the ongoing risk of disruption from new, potentially more cost-effective or efficient technologies being developed by competitors or academic groups (e.g., enzymatic or nanopore-based DNA synthesis). The company operates in a highly competitive landscape against established players with greater resources and extensive intellectual property portfolios, such as GenScript, Integrated DNA Technologies (IDT), Thermo Fisher Scientific, Eurofins Scientific, and Danaher's IDT. Intellectual property challenges are also an existential risk in this high-stakes market.
  3. Market Adoption and Execution Challenges in Emerging Areas: Twist Bioscience is expanding into nascent and high-potential markets such as DNA data storage and biopharma drug discovery. While these represent significant growth opportunities, they also carry inherent risks related to the speed of market adoption, the company's ability to effectively execute its strategy in these complex fields, and the extensive investment required for research and development. For example, the widespread adoption of DNA data storage still faces hurdles related to cost and speed.

AI Analysis | Feedback

null

AI Analysis | Feedback

Twist Bioscience (TWST) operates in several key addressable markets for its synthetic DNA-based products and services:

Synthetic DNA and Synthetic Biology

  • The global DNA synthesis market size was estimated at USD 3.52 billion in 2024 and is projected to reach USD 13.85 billion by 2033, growing at a CAGR of 16.89% from 2025 to 2033.
  • Another estimate values the global DNA synthesis market size at US$ 5.42 billion in 2025, growing to US$ 6.37 billion in 2026, and projected to reach around US$ 27.03 billion by 2035 at a CAGR of 17.42% between 2026 and 2035.
  • The global synthetic DNA market was valued at US$3.7 billion in 2024 and is projected to reach US$10.3 billion by 2030, growing at a CAGR of 18.7% from 2024 to 2030.
  • The U.S. DNA synthesis market size was estimated at USD 1.25 billion in 2024 and is projected to reach USD 4.62 billion by 2033, expanding at a CAGR of 15.93% from 2025 to 2033.
  • North America held the largest share of the global DNA synthesis market, with approximately 39.83% in 2024.
  • The broader global synthetic biology market size was valued at USD 25.6 billion in 2025 and is set to expand to USD 128.1 billion by 2035, advancing at a 17.5% CAGR from 2026 to 2035. North America is the largest market for synthetic biology.

Tools for Sample Preparation (Genomics)

  • The global sample preparation market size was estimated at USD 7.88 billion in 2024 and is projected to reach USD 11.27 billion by 2030, growing at a CAGR of 6.1% from 2025 to 2030.
  • Another report states the global sample preparation market size was valued at approximately USD 7.35 billion in 2024 and is predicted to reach around USD 13.41 billion by the end of 2034, expanding at a CAGR of around 6.2% from 2025 to 2034.
  • North America was the largest region in the sample preparation market in 2025. The U.S. sample preparation market is primarily driven by advancements in biopharmaceutical research, drug discovery, and clinical diagnostics.
  • The genomics segment dominated the sample preparation market in 2024, with a share of 30.94%, and is expected to witness the fastest growth rate.
  • The global NGS (Next-Generation Sequencing) sample preparation market size is projected to reach USD 11,774.7 million by 2033, with a CAGR of 15.8% from 2025 to 2033. The U.S. NGS sample preparation market size is USD 1063.1 million in 2025 and is predicted to evolve at a CAGR of 14% over the analysis period.

Antibody Libraries for Drug Discovery and Development

  • The global antibody library technology market is anticipated to reach a size of US$ 1.7 billion by 2025. It is set to showcase a CAGR of 4.1% during the forecast period to attain a value of US$ 2.2 billion by 2032.
  • Another estimate for the global antibody library technology market is US$ 165.7 million in revenue in 2024, expected to expand at a CAGR of 3.98%, reaching an estimated valuation of US$ 217.8 million by the end of 2031.
  • The global antibody discovery market size was valued at USD 6.9 billion in 2022 and is projected to reach USD 17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032.
  • The global human combinatorial antibody libraries market size is calculated at US$ 116.2 million in 2024, grew to US$ 122 million in 2025, and is projected to reach around US$ 189.57 million by 2034, expanding at a CAGR of 5.04% between 2025 and 2034. North America dominates the human combinatorial antibody libraries market in 2024.

DNA as a Digital Data Storage Medium

  • The global DNA data storage market was valued at USD 145.8 million in 2025. The market is expected to grow from USD 272.8 million in 2026 to USD 6.3 billion in 2031 and USD 80.2 billion in 2035, at a value CAGR of 88% during the forecast period.
  • Another estimate projects the global DNA data storage market to reach USD 44,213.05 million by 2034, growing at a CAGR of 88.01% from 2025 to 2034.
  • The U.S. DNA data storage market was valued at USD 44.9 million in 2025. The U.S. is the largest single national market for DNA data storage.
  • Twist Bioscience spun out its DNA data storage division into an independent company, Atlas Data Storage, in May 2025.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Twist Bioscience (symbol: TWST) over the next 2-3 years:

  1. Expansion in AI-driven Drug Discovery and Biopharma Services: Twist Bioscience anticipates significant revenue growth from increased demand in the therapeutic sector, particularly from customers engaged in AI-enabled drug discovery and development. Orders from customers working on AI discovery projects grew by over $25 million in fiscal 2024, and the company continues to see strong demand from customers building models or testing molecules using its DNA synthesis and protein solutions.
  2. Growth in Next-Generation Sequencing (NGS) Applications, especially Minimal Residual Disease (MRD) Testing: The company expects continued growth in its NGS applications, driven by demand from liquid biopsy and rare disease diagnostics. The commercial launch of new products such as MRD Express in early calendar 2026, with planned commercial scaling into 2027, is anticipated to be a significant contributor to revenue. Additionally, Twist is launching new library preparation kits like the TrueAmp library prep kit and PCR-Free WGS Library Preparation Kit to expand its reach in the whole genome sequencing market and address challenging sample types for clinical research.
  3. Expansion of Served Addressable Market (SAM) through New Product Introductions and Market Diversification: Twist Bioscience aims to expand its served addressable market from $7 billion to $12 billion by 2030 through the introduction of new products and solutions. This includes entering new market segments with GMP-grade products, focusing on the RNA segment, and exploring new market opportunities such as AgBio. The company is also launching new plasmid preps to support nucleic acid therapeutics research.
  4. Increased Customer Acquisition and Diversification: Twist Bioscience is actively working to expand its customer base and diversify its revenue streams. Efforts include leveraging its Express Genes portfolio to gain traction within the academic market and shifting its sales emphasis beyond solely large pharmaceutical accounts. This strategy has resulted in an influx of net new customers and is designed to build a broader and more resilient customer base.

AI Analysis | Feedback

Twist Bioscience (TWST) has made the following capital allocation decisions over the last 3-5 years:

Share Repurchases

  • Twist Bioscience repurchased common stock valued at $4.0 million in 2024.
  • The company's common stock repurchases amounted to $4.4 million in 2023.
  • Share repurchases totaled $7.8 million in 2022.

Share Issuance

  • Twist Bioscience issued $269.8 million in common stock during 2022.
  • The company also issued $323.9 million in common stock in 2021.
  • The number of shares outstanding has shown a consistent increase over the past several years, growing by 2.93% in the last year alone.

Outbound Investments

  • Twist Bioscience's "Purchase of investments" totaled $51.9 million in 2024.
  • "Purchase of investments" amounted to $76.3 million in 2023.
  • The company's "Purchase of investments" reached $217.6 million in 2022, and net acquisitions were $13.9 million in the same year.

Capital Expenditures

  • Capital expenditures for Twist Bioscience were $5.1 million in 2024.
  • The company's capital expenditures were $27.8 million in 2023.
  • In 2022, capital expenditures reached $101.9 million and are primarily focused on expanding and enhancing its proprietary silicon-based DNA synthesis platform and manufacturing processes.

Better Bets vs. Twist Bioscience (TWST)

Peer Outperformance in Biotechnology

TWST has outperformed 80% of its 369 Biotechnology peers over 5Y. Among the peers that beat it is LGND. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that TWST has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
99%
of 452 industry peers · 347.5% return
3Y
93%
of 399 industry peers · 384.6% return
5Y
80%
of 369 industry peers · 3.7% return
Biotechnology peers with revenue growth within 4pp of TWST's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
TWST Twist Bioscience 23.3% -59.5x 347.5%384.6%3.7% —
LGND Ligand Pharmaceuticals 21.7% 115.9x 44.3%416.6%85.8% +82pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is TWST's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology ← 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

TWSTDNAILMNTMOCDXSTXGMedian
NameTwist Bi.Ginkgo B.Illumina Thermo F.Codexis 10x Geno. 
Mkt Price118.188.44210.01695.491.1457.2887.73
Mkt Cap7.90.531.7257.30.17.57.7
Rev LTM4591314,53847,35188619539
Op Inc LTM-132-2659708,863-13-76-44
FCF LTM-96-1741,0577,596-129441
FCF 3Y Avg-80-2498687,161-406713
CFO LTM-41-1671,2309,324-1010045
CFO 3Y Avg-51-2231,0168,692-377620

Growth & Margins

TWSTDNAILMNTMOCDXSTXGMedian
NameTwist Bi.Ginkgo B.Illumina Thermo F.Codexis 10x Geno. 
Rev Chg LTM22.0%-13.2%5.8%8.3%66.9%-3.6%7.0%
Rev Chg 3Y Avg23.3%-25.0%0.6%3.0%12.1%1.6%2.3%
Rev Chg Q27.9%-5.7%4.2%9.1%124.0%1.1%6.6%
QoQ Delta Rev Chg LTM6.4%-1.3%1.0%2.2%13.7%0.3%1.6%
Op Inc Chg LTM2.8%15.2%21.6%10.1%78.6%46.5%18.4%
Op Inc Chg 3Y Avg13.4%30.4%160.0%6.7%27.7%24.7%26.2%
Op Mgn LTM-28.8%-202.5%21.4%18.7%-14.4%-12.2%-13.3%
Op Mgn 3Y Avg-40.4%-223.2%15.1%18.2%-68.6%-21.0%-30.7%
QoQ Delta Op Mgn LTM3.1%26.1%1.5%0.4%16.8%2.7%2.9%
CFO/Rev LTM-9.0%-127.7%27.1%19.7%-11.9%16.1%3.6%
CFO/Rev 3Y Avg-14.0%-130.5%23.0%19.6%-61.9%12.0%-1.0%
FCF/Rev LTM-20.9%-132.7%23.3%16.0%-13.7%15.2%0.7%
FCF/Rev 3Y Avg-21.0%-144.9%19.7%16.1%-67.5%10.6%-5.2%

Valuation

TWSTDNAILMNTMOCDXSTXGMedian
NameTwist Bi.Ginkgo B.Illumina Thermo F.Codexis 10x Geno. 
Mkt Cap7.90.531.7257.30.17.57.7
P/S17.14.17.05.41.412.16.2
P/Op Inc-59.5-2.032.729.0-9.6-99.1-5.8
P/EBIT-59.5-2.027.427.3-8.9-108.0-5.4
P/E-60.5-2.235.436.4-6.3-111.7-4.2
P/CFO-190.1-3.225.827.6-11.675.111.3
Total Yield-1.7%-46.5%2.8%3.0%-15.6%-0.9%-1.3%
Dividend Yield0.0%0.0%0.0%0.3%0.0%0.0%0.0%
FCF Yield 3Y Avg-2.6%-45.1%4.0%3.2%-19.0%2.4%-0.1%
D/E0.00.70.10.20.60.00.1
Net D/E-0.10.20.00.1-0.0-0.10.0

Returns

TWSTDNAILMNTMOCDXSTXGMedian
NameTwist Bi.Ginkgo B.Illumina Thermo F.Codexis 10x Geno. 
1M Rtn-15.4%-16.2%-20.0%2.4%-14.0%-18.0%-15.8%
3M Rtn-17.0%9.5%2.4%13.4%-29.1%-7.9%-2.7%
6M Rtn120.2%9.3%48.0%54.2%-56.0%138.9%51.1%
12M Rtn354.5%7.8%72.2%21.2%-30.8%268.1%46.7%
3Y Rtn392.2%-86.1%129.1%50.6%-44.4%35.8%43.2%
1M Excs Rtn-13.3%-10.6%-17.8%5.0%-3.9%-16.0%-11.9%
3M Excs Rtn-10.3%24.2%1.4%13.9%-25.3%-7.4%-3.0%
6M Excs Rtn120.5%9.5%48.2%54.4%-55.8%139.1%51.3%
12M Excs Rtn335.3%-2.7%63.7%11.9%-38.7%253.6%37.8%
3Y Excs Rtn515.5%-151.6%64.8%-10.6%-98.9%-10.7%-10.6%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20262025202420232022
Next-Generation Sequencing (NGS) applications23820816912499
DNA synthesis and protein solutions222168144  
Antibody discovery   2324
DNA libraries   106
Oligo pools   1412
Synthetic genes   7462
Total459377313245204


Price Behavior

Price Behavior
Market Price$116.35 
Market Cap ($ Bil)7.8 
First Trading Date10/31/2018 
Distance from 52W High-43.2% 
   50 Days200 Days
DMA Price$149.33$94.23
DMA Trendupup
Distance from DMA-22.1%23.5%
 3M1YR
Volatility104.9%83.8%
Downside Capture401.29237.67
Upside Capture333.98372.61
Correlation (S&P 500)49.8%48.3%
TWST Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta5.353.203.382.942.812.28
Up Beta6.100.96-1.211.442.131.87
Down Beta5.238.678.353.822.611.85
Up Capture383%242%594%797%1827%19117%
Bmk +ve Days12182862130427
Stock +ve Days10213264133381
Down Capture544%124%148%165%156%113%
Bmk -ve Days10253664121325
Stock -ve Days11213161117369

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TWST
TWST342.3%83.8%2.13-
Sector ETF (XLV)21.5%17.0%0.9626.9%
Equity (SPY)10.9%13.8%0.4946.9%
Gold (GLD)-8.2%29.0%-0.3026.1%
Commodities (DBC)28.8%21.5%1.07-15.1%
Real Estate (VNQ)11.2%14.2%0.5011.8%
Bitcoin (BTCUSD)-29.6%43.7%-0.6922.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TWST
TWST0.7%79.6%0.35-
Sector ETF (XLV)8.0%15.4%0.3337.1%
Equity (SPY)11.0%17.3%0.4652.3%
Gold (GLD)14.5%19.2%0.6014.4%
Commodities (DBC)6.8%19.6%0.241.5%
Real Estate (VNQ)1.1%19.0%-0.0539.3%
Bitcoin (BTCUSD)-0.0%51.4%0.1829.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with TWST
TWST24.3%79.7%0.70-
Sector ETF (XLV)12.1%16.8%0.5934.4%
Equity (SPY)14.9%18.0%0.7044.7%
Gold (GLD)10.9%16.6%0.5313.9%
Commodities (DBC)7.2%18.2%0.318.8%
Real Estate (VNQ)5.8%20.7%0.2433.6%
Bitcoin (BTCUSD)57.1%66.3%0.9723.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity9.8 Mil
Short Interest: % Change Since 10152026-3.6%
Average Daily Volume2.3 Mil
Days-to-Cover Short Interest4.4 days
Basic Shares Quantity66.6 Mil
Short % of Basic Shares14.8%

Earnings Returns History

Updated 11/17/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-6.8%  
8/3/202610.4%26.3%51.8%
5/4/2026-7.0%-5.9%16.1%
2/2/202614.0%19.9%13.6%
11/14/2025-10.1%-12.8%4.1%
8/4/2025-10.3%-23.9%-22.1%
5/5/2025-8.4%-21.5%-21.3%
2/3/20250.7%-0.1%-24.2%
...
SUMMARY STATS   
# Positive121011
# Negative131413
Median Positive11.6%12.4%25.1%
Median Negative-8.4%-13.3%-18.5%
Max Positive28.7%35.0%81.2%
Max Negative-20.1%-23.9%-46.6%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-6.8%  
8/3/202610.4%26.3%51.8%
5/4/2026-7.0%-5.9%16.1%
2/2/202614.0%19.9%13.6%
11/14/2025-10.1%-12.8%4.1%
8/4/2025-10.3%-23.9%-22.1%
5/5/2025-8.4%-21.5%-21.3%
2/3/20250.7%-0.1%-24.2%
11/18/202412.3%14.5%31.2%
8/2/2024-19.0%-14.4%-18.5%
5/2/202428.7%35.0%37.5%
2/2/202410.0%9.8%15.0%
11/17/202325.9%28.4%81.2%
8/4/202311.2%10.3%14.0%
5/5/2023-0.4%-1.9%25.1%
2/3/2023-18.1%-20.2%-39.0%
11/18/2022-2.3%0.2%-6.3%
8/5/202212.7%4.8%-17.2%
5/5/20220.8%-5.3%-3.4%
2/4/2022-2.4%1.1%-21.8%
11/22/2021-1.5%-2.7%-12.5%
8/6/2021-10.8%-13.8%-7.6%
5/6/202111.9%-15.5%-2.4%
2/4/2021-20.1%-16.3%-46.6%
11/23/20201.4%-3.3%45.3%
SUMMARY STATS   
# Positive121011
# Negative131413
Median Positive11.6%12.4%25.1%
Median Negative-8.4%-13.3%-18.5%
Max Positive28.7%35.0%81.2%
Max Negative-20.1%-23.9%-46.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/16/202610-K
06/30/202608/03/202610-Q
03/31/202605/04/202610-Q
12/31/202502/02/202610-Q
09/30/202511/17/202510-K
06/30/202508/04/202510-Q
03/31/202505/05/202510-Q
12/31/202402/03/202510-Q
09/30/202411/18/202410-K
06/30/202408/02/202410-Q
03/31/202405/02/202410-Q
12/31/202302/02/202410-Q
09/30/202311/21/202310-K
06/30/202308/07/202310-Q
03/31/202305/08/202310-Q
12/31/202202/07/202310-Q
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/16/202610-K
06/30/202608/03/202610-Q
03/31/202605/04/202610-Q
12/31/202502/02/202610-Q
09/30/202511/17/202510-K
06/30/202508/04/202510-Q
03/31/202505/05/202510-Q
12/31/202402/03/202510-Q
09/30/202411/18/202410-K
06/30/202408/02/202410-Q
03/31/202405/02/202410-Q
12/31/202302/02/202410-Q
09/30/202311/21/202310-K
06/30/202308/07/202310-Q
03/31/202305/08/202310-Q
12/31/202202/07/202310-Q
09/30/202211/28/202210-K
06/30/202208/08/202210-Q
03/31/202205/06/202210-Q
12/31/202102/09/202210-Q
09/30/202111/23/202110-K
06/30/202108/09/202110-Q
03/31/202105/07/202110-Q
12/31/202002/09/202110-Q
09/30/202011/27/202010-K
06/30/202008/12/202010-Q
03/31/202005/13/202010-Q
12/31/201902/10/202010-Q

Recent Forward Guidance

Updated 11/13/2026

Latest: Q4 2026 Earnings Reported 11/12/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q1 2027 RevenueReported130.00 Mil131.00 Mil132.00 Mil6.1% Higher NewGuidance: 123.50 Mil for Q4 2026
Q1 2027 Revenue GrowthReported 26.0%  1.0%Higher NewGuidance: 25.0% for Q4 2026
2027 RevenueReported550.00 Mil555.00 Mil560.00 Mil21.6% Higher NewGuidance: 456.50 Mil for 2026
2027 Revenue GrowthReported 21.0%  0.0%Same NewGuidance: 21.0% for 2026
2027 AI Drug Discovery RevenueReported 100.00 Mil    
2027 Gross MarginReported52.5%52.75%53.0% 0.8%Higher NewGuidance: 52.0% for 2026
2027 Adjusted EBITDAReported      
2027 Capital ExpendituresReported 75.00 Mil    


Prior: Q3 2026 Earnings Reported 8/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q4 2026 RevenueReported123.00 Mil123.50 Mil124.00 Mil   
Q4 2026 Revenue GrowthReported 25.0%    
Q4 2026 Adjusted EBITDAReported 0   AffirmedGuidance: 0 for Q4 2026
2026 RevenueReported456.00 Mil456.50 Mil457.00 Mil2.7% RaisedGuidance: 444.50 Mil for 2026
2026 Revenue GrowthReported 21.0%  3.0%RaisedGuidance: 18.0% for 2026
2026 Gross ProfitCalculated237.12 Mil237.38 Mil237.64 Mil  Rev x Gross Margin
2026 Gross MarginReported 52.0%  0AffirmedGuidance: 52.0% for 2026

Q2 2026 Earnings Reported 5/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q3 2026 RevenueReported114.00 Mil114.50 Mil115.00 Mil6.5% Higher NewActual: 107.50 Mil for Q2 2026
Q3 2026 Revenue GrowthReported 19.0%  3.0%Higher NewActual: 16.0% for Q2 2026
Q4 2026 Adjusted EBITDAReported 0    
2026 RevenueReported442.00 Mil444.50 Mil447.00 Mil1.6% RaisedGuidance: 437.50 Mil for 2026
2026 Revenue GrowthReported17.0%18.0%19.0% 2.0%RaisedGuidance: 16.0% for 2026
2026 Gross ProfitCalculated229.84 Mil231.14 Mil232.44 Mil  Rev x Gross Margin
2026 Gross MarginReported 52.0%  0AffirmedGuidance: 52.0% for 2026

Q1 2026 Earnings Reported 2/2/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q2 2026 RevenueReported107.00 Mil107.50 Mil108.00 Mil7.0% Higher NewGuidance: 100.50 Mil for Q1 2026
Q2 2026 Revenue GrowthReported 16.0%    
2026 RevenueReported435.00 Mil437.50 Mil440.00 Mil1.7% RaisedGuidance: 430.00 Mil for 2026
2026 Revenue GrowthReported 16.0%  1.8%RaisedGuidance: 14.25% for 2026
2026 Gross ProfitCalculated226.20 Mil227.50 Mil228.80 Mil  Rev x Gross Margin
2026 Gross MarginReported 52.0%  0.0%AffirmedGuidance: 52.0% for 2026

Insider Activity

Updated 11/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Cho, DennisSee RemarksDirectSell11182026103.695,427562,7158,319,718Form
2Finn, Patrick JohnPresident and COODirectSell11182026103.6912,7521,322,22922,931,742Form
3Green, PaulaSVP of Human ResourcesDirectSell11182026103.694,281443,88812,626,399Form
4Leproust, Emily MChief Executive OfficerDirectSell11182026103.6919,0451,974,73865,789,310Form
5Werner, Robert FChief Accounting OfficerDirectSell11182026103.691,637169,7375,139,918Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Cho, DennisSee RemarksDirectSell11182026103.695,427562,7158,319,718Form
2Finn, Patrick JohnPresident and COODirectSell11182026103.6912,7521,322,22922,931,742Form
3Green, PaulaSVP of Human ResourcesDirectSell11182026103.694,281443,88812,626,399Form
4Leproust, Emily MChief Executive OfficerDirectSell11182026103.6919,0451,974,73865,789,310Form
5Werner, Robert FChief Accounting OfficerDirectSell11182026103.691,637169,7375,139,918Form
6Laponis, AdamChief Financial OfficerDirectSell11182026103.696,359659,35212,287,132Form
7Green, PaulaSVP of Human ResourcesDirectSell111620260.0020,429  Form
8Cho, DennisSee RemarksDirectSell11052026135.40949128,4968,508,662Form
9Finn, Patrick JohnPresident and COODirectSell11052026135.402,565347,30624,410,002Form
10Leproust, Emily MChief Executive OfficerDirectSell11052026135.404,573619,19375,579,636Form
11Werner, Robert FChief Accounting OfficerDirectSell11052026135.4014820,0395,791,008Form
12Green, PaulaSVP of Human ResourcesDirectSell11052026135.401,007136,35014,301,836Form
13Finn, Patrick JohnPresident and COODirectSell10272026134.592,245302,15224,608,657Form
14Laponis, AdamChief Financial OfficerDirectSell10132026156.302,462384,82315,335,699Form
15Leproust, Emily MChief Executive OfficerDirectSell10072026202.154,548919,374113,761,372Form
16Laponis, AdamChief Financial OfficerDirectSell10052026188.888,0571,521,83818,997,197Form
17Green, PaulaSVP of Human ResourcesDirectSell10052026188.8810,0881,905,46220,141,079Form
18Finn, Patrick JohnPresident and COODirectSell10052026188.8825,7144,856,96334,960,162Form
19Leproust, Emily MChief Executive OfficerDirectSell10052026188.8845,7368,638,799107,155,404Form
20Cho, DennisSee RemarksDirectSell10052026188.889,5141,797,04212,048,721Form
21Werner, Robert FChief Accounting OfficerDirectSell10052026188.881,482279,9268,106,335Form
22Leproust, Emily MChief Executive OfficerDirectSell10052026200.00655131,000122,608,800Form
23Leproust, Emily MChief Executive OfficerDirectSell9252026177.385,203922,907108,857,740Form
24Cho, DennisSee RemarksDirectSell9232026165.4934857,59112,130,987Form
25Green, PaulaSVP of Human ResourcesDirectSell9232026165.4929448,65419,316,110Form
26Leproust, Emily MChief Executive OfficerDirectSell9232026165.491,687279,183102,422,711Form
27Leproust, Emily MChief Executive OfficerDirectSell9212026157.99356,54656,330,72498,046,894Form
28Cho, DennisSee RemarksDirectSell9102026122.6241250,5219,031,380Form
29Green, PaulaSVP of Human ResourcesDirectSell9102026122.62907111,22014,348,725Form
30Leproust, Emily MChief Executive OfficerDirectSell9102026122.622,302282,28094,227,592Form
31Werner, Robert FChief Accounting OfficerDirectSell9102026122.6223829,1855,444,383Form
32Leproust, Emily MChief Executive OfficerDirectSell8272026151.9841,5706,317,760117,134,483Form
33Werner, Robert FChief Accounting OfficerDirectSell8252026140.77854120,2206,283,684Form
34Cho, DennisSee RemarksDirectSell8252026139.071,598222,22710,299,645Form
35Finn, Patrick JohnPresident and COODirectSell8252026139.074,046562,66129,315,391Form
36Green, PaulaSVP of Human ResourcesDirectSell8252026139.071,360189,13016,398,802Form
37Laponis, AdamChief Financial OfficerDirectSell8252026139.071,965273,26515,107,157Form
38Leproust, Emily MChief Executive OfficerDirectSell8252026139.076,639923,259112,963,173Form
39Werner, Robert FChief Accounting OfficerDirectSell8252026139.0766993,0356,326,251Form
40Cho, DennisSee RemarksDirectSell8212026129.7514,2051,843,0999,817,015Form
41Finn, Patrick JohnPresident and COODirectSell8202026117.6478,3559,217,60725,254,513Form
42Blake, KatrynDirectSell8142026122.882,240275,2512,114,519Form
43Leproust, Emily MChief Executive OfficerDirectSell8142026125.0819,9522,495,508102,429,162Form
44Leproust, Emily MChief Executive OfficerDirectSell8122026125.16113,31814,183,051102,499,508Form
45Chess, RobertDirectSell8112026110.8918,4172,042,2612,338,005Form
46Cho, DennisSee RemarksDirectSell8072026109.7514,2051,558,9999,862,794Form
47Finn, Patrick JohnPresident and COODirectSell805202685.322,888246,40823,009,251Form
48Green, PaulaSVP of Human ResourcesDirectSell805202685.321,13396,66910,177,198Form
49Leproust, Emily MChief Executive OfficerDirectSell805202685.325,101435,22369,872,773Form
50Werner, Robert FChief Accounting OfficerDirectSell805202685.3216714,2493,938,427Form
51Cho, DennisSee RemarksDirectSell805202685.321,07091,2948,879,463Form
52Finn, Patrick JohnPresident and COODirectSell727202693.892,238210,13325,592,039Form
53Laponis, AdamChief Financial OfficerDirectSell713202694.332,399226,30710,402,776Form
54Cho, DennisSee RemarksDirectSell626202689.7514,2051,274,8999,436,405Form
55Green, PaulaSVP of Human ResourcesDirectSell624202687.3229125,41110,514,839Form
56Cho, DennisSee RemarksDirectSell624202687.3234630,21410,421,579Form
57Leproust, Emily MChief Executive OfficerDirectSell624202687.321,688147,40073,605,710Form
58Green, PaulaSVP of Human ResourcesDirectSell617202681.6726,1372,134,4889,857,418Form
59Cho, DennisSee RemarksDirectSell610202669.8440228,0778,359,792Form
60Green, PaulaSVP of Human ResourcesDirectSell610202669.8488461,7428,430,544Form
61Leproust, Emily MChief Executive OfficerDirectSell610202669.842,265158,19758,990,900Form
62Werner, Robert FChief Accounting OfficerDirectSell610202669.201,35994,0463,240,530Form
63Cho, DennisSee RemarksDirectSell602202669.7514,205990,7998,376,556Form
64Laponis, AdamChief Financial OfficerDirectSell602202670.004,000280,0007,887,250Form
65Leproust, Emily MChief Executive OfficerDirectSell601202667.9116,4701,118,55557,515,030Form
66Starovasnik, Melissa ADirectSell601202668.002,500170,0001,511,096Form
67Leproust, Emily MChief Executive OfficerDirectSell528202665.2925,0171,633,40755,293,877Form
68Starovasnik, Melissa ADirectSell528202661.0450030,5201,509,031Form
69Leproust, Emily MChief Executive OfficerDirectSell528202665.0824,2821,580,24655,113,498Form
70Werner, Robert FChief Accounting OfficerDirectSell528202662.4880049,9873,010,854Form
71Green, PaulaSVP of Human ResourcesDirectSell526202653.261,39974,5076,475,465Form
72Finn, Patrick JohnPresident and COODirectSell526202653.264,160221,54914,635,237Form
73Cho, DennisSee RemarksDirectSell526202653.261,64287,4487,152,362Form
74Werner, Robert FChief Accounting OfficerDirectSell526202653.2668836,6412,608,847Form
75Leproust, Emily MChief Executive OfficerDirectSell526202653.266,888366,83445,101,862Form
76Laponis, AdamChief Financial OfficerDirectSell526202653.262,019107,5266,213,760Form
77Johannessen, JanDirectSell514202656.1212,000673,440996,354Form
78Werner, Robert FChief Accounting OfficerDirectSell512202656.884,961282,1872,825,507Form
79Cho, DennisSee RemarksDirectSell506202657.151,962112,1267,768,865Form
80Leproust, Emily MChief Executive OfficerDirectSell506202657.155,127293,00248,791,359Form
81Finn, Patrick JohnPresident and COODirectSell506202657.152,844162,53115,942,458Form
82Green, PaulaSVP of Human ResourcesDirectSell506202657.151,11663,7787,028,617Form
83Werner, Robert FChief Accounting OfficerDirectSell506202657.151649,3723,122,325Form
84Starovasnik, Melissa ADirectSell429202661.8350030,9151,559,476Form
85Finn, Patrick JohnPresident and COODirectSell427202660.762,321141,02617,122,936Form
86Leproust, Emily MChief Executive OfficerDirectSell423202665.298,061526,29156,075,513Form
87Leproust, Emily MChief Executive OfficerDirectSell423202665.011,610104,66655,836,244Form
88Laponis, AdamChief Financial OfficerDirectSell421202660.004,000240,0007,121,640Form
89Laponis, AdamChief Financial OfficerDirectSell416202655.003,000165,0006,748,170Form
90Laponis, AdamChief Financial OfficerDirectSell413202649.892,597129,5626,270,748Form
91Starovasnik, Melissa ADirectSell403202651.001,00051,0001,311,822Form
92Cho, DennisSee RemarksDirectSell324202643.7935415,5006,038,276Form
93Green, PaulaSVP of Human ResourcesDirectSell324202643.7929713,0055,434,067Form
94Leproust, Emily MChief Executive OfficerDirectSell324202643.791,74276,27637,607,570Form
95Chess, RobertDirectSell319202647.0010,000470,000990,948Form
96Werner, Robert FChief Accounting OfficerDirectSell310202646.4324611,4212,544,098Form
97Cho, DennisSee RemarksDirectSell310202646.4342519,7316,418,719Form
98Green, PaulaSVP of Human ResourcesDirectSell310202646.4393543,4085,775,441Form
99Leproust, Emily MChief Executive OfficerDirectSell310202646.432,423112,49039,955,562Form
100Finn, Patrick JohnPresident and COODirectSell225202646.714,294200,57213,271,609Form
101Werner, Robert FChief Accounting OfficerDirectSell225202646.711,69379,0802,571,141Form
102Laponis, AdamChief Financial OfficerDirectSell225202646.712,08597,3905,992,447Form
103Leproust, Emily MChief Executive OfficerDirectSell225202646.717,205336,54440,312,986Form
104Green, PaulaSVP of Human ResourcesDirectSell225202646.711,46568,4305,854,419Form
105Cho, DennisSee RemarksDirectSell225202646.7184439,4236,477,808Form
106Chess, RobertDirectSell218202648.262,184105,4021,017,535Form
107Finn, Patrick JohnPresident and COODirectSell217202650.041,75087,57215,325,056Form
108Finn, Patrick JohnPresident and COODirectSell217202650.233,500175,78815,408,427Form
109Laponis, AdamChief Financial OfficerDirectSell213202650.007,000350,0006,501,550Form
110Cho, DennisSee RemarksDirectSell213202649.935,000249,6506,919,349Form
111Johannessen, JanDirectSell209202647.912,200105,395850,536Form
112Werner, Robert FChief Accounting OfficerDirectSell205202645.657,000319,5362,681,272Form
113Finn, Patrick JohnPresident and COODirectSell205202646.582,705125,98814,335,534Form
114Leproust, Emily MChief Executive OfficerDirectSell205202646.585,001232,92740,489,076Form
115Werner, Robert FChief Accounting OfficerDirectSell205202646.581758,1513,061,813Form
116Green, PaulaSVP of Human ResourcesDirectSell205202646.581,19455,6127,705,766Form
117Cho, DennisSee RemarksDirectSell205202646.581,09951,1876,687,429Form
118Finn, Patrick JohnPresident and COODirectSell127202644.912,390107,33013,943,620Form
119Laponis, AdamChief Financial OfficerDirectSell113202635.262,73896,5454,937,633Form
120Green, PaulaSVP of Human ResourcesDirectSell1223202534.562739,4345,758,377Form
121Cho, DennisSee RemarksDirectSell1223202534.5632411,1964,999,562Form
122Leproust, Emily MChief Executive OfficerDirectSell1223202534.561,60555,46230,212,760Form
123Cho, DennisSee RemarksDirectSell1210202532.8839813,0854,767,442Form
124Leproust, Emily MChief Executive OfficerDirectSell1210202532.882,25574,14028,798,432Form
125Green, PaulaSVP of Human ResourcesDirectSell1210202532.8887728,8345,487,733Form
126Werner, Robert FChief Accounting OfficerDirectSell1210202532.882307,5622,167,088Form
127Werner, Robert FChief Accounting OfficerDirectSell1125202528.7182223,5991,898,932Form
128Cho, DennisSee RemarksDirectSell1125202526.5075720,0633,853,662Form
129Finn, Patrick JohnPresident and COODirectSell1125202526.501,77647,0708,822,565Form
130Green, PaulaSVP of Human ResourcesDirectSell1125202526.5059815,8494,446,996Form
131Laponis, AdamChief Financial OfficerDirectSell1125202526.5088723,5093,783,878Form
132Leproust, Emily MChief Executive OfficerDirectSell1125202526.502,66370,57923,274,658Form
133Werner, Robert FChief Accounting OfficerDirectSell1125202526.502296,0691,774,807Form
134Johannessen, JanDirectSell1120202524.777,044174,480368,057Form
135Cho, DennisSee RemarksDirectSell1105202532.081,01932,6893,871,791Form
136Finn, Patrick JohnPresident and COODirectSell1105202532.082,75588,3798,530,522Form
137Green, PaulaSVP of Human ResourcesDirectSell1105202532.081,08434,7744,561,274Form
138Leproust, Emily MChief Executive OfficerDirectSell1105202532.084,887156,77223,543,777Form
139Werner, Robert FChief Accounting OfficerDirectSell1105202532.081605,1331,631,879Form
140Cho, DennisSee RemarksDirectSell1103202531.446,515204,8603,827,180Form
141Finn, Patrick JohnPresident and COODirectSell1103202531.4417,606553,6088,448,266Form
142Green, PaulaSVP of Human ResourcesDirectSell1103202531.446,920217,5954,505,056Form
143Leproust, Emily MChief Executive OfficerDirectSell1103202531.4431,379986,69123,231,332Form
144Laponis, AdamChief Financial OfficerDirectSell1103202531.445,517173,4783,490,569Form
145Werner, Robert FChief Accounting OfficerDirectSell1103202531.441,01631,9471,604,603Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$41.8 Mil3.7%35TRIM -23.0%13F
EdgePoint Investment Group Inc.$255.8 Mil2.1%37Hold13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$41.8 Mil3.7%35TRIM -23.0%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
EdgePoint Investment Group Inc.$255.8 Mil2.1%37Hold13F
First Light Asset Management, LLC$41.8 Mil3.7%35TRIM -23.0%13F
Core Cache Last Updated: 11/18/2026